Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -928.44% is 160% below its 5-year average of -356.69%, around the middle of its 5-year range (-1394.34%–-79.14%).
11.75% below its 12-month average of -830.80%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-05-31): -990.10%.
NET PROFIT MARGIN
-928.44%
NET PROFIT MARGIN AVG TTM
-830.80%
NET PROFIT MARGIN AVG 3Y
-361.35%
NET PROFIT MARGIN AVG 5Y
-356.69%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-11.75%
CURRENT VS 3Y AVG
-156.94%
CURRENT VS 5Y AVG
-160.29%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 791 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Nurix Therapeutics, Inc.
Market Cap
$2.34B
Net Profit Margin
-928.44%
TTM Avg
-830.80%
3Y Avg
-361.35%
5Y Avg
-356.69%
Market Cap
$2.34B
Net Profit Margin
30.74%
TTM Avg
-487.59%
3Y Avg
-420.36%
5Y Avg
-1671.77%
Market Cap
$2.37B
Net Profit Margin
32.98%
TTM Avg
37.58%
3Y Avg
5.36%
5Y Avg
-41.08%
Market Cap
$2.30B
Net Profit Margin
18.88%
TTM Avg
19.31%
3Y Avg
25.55%
5Y Avg
15.07%
Market Cap
$2.39B
Net Profit Margin
-945.92%
TTM Avg
-825.68%
3Y Avg
-750.64%
5Y Avg
-1236.10%
Market Cap
$2.28B
Net Profit Margin
-37.07%
TTM Avg
-63.15%
3Y Avg
-35.64%
5Y Avg
-15.45%
Market Cap
$2.40B
Net Profit Margin
-0.74%
TTM Avg
-3.79%
3Y Avg
-13.87%
5Y Avg
-19.28%
Market Cap
$2.42B
Net Profit Margin
-40.18%
TTM Avg
-20.09%
3Y Avg
-20.09%
5Y Avg
-20.09%
Market Cap
$2.42B
Net Profit Margin
-13.23%
TTM Avg
2.90%
3Y Avg
3.78%
5Y Avg
8.12%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | $2.34B | -928.44% | -830.80% | -361.35% | -356.69% |
| Liquidia Corporation (LQDA)vs › | $2.34B | 30.74% | -487.59% | -420.36% | -1671.77% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.37B | 32.98% | 37.58% | 5.36% | -41.08% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.30B | 18.88% | 19.31% | 25.55% | 15.07% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.39B | -945.92% | -825.68% | -750.64% | -1236.10% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.28B | -37.07% | -63.15% | -35.64% | -15.45% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | -0.74% | -3.79% | -13.87% | -19.28% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.42B | -40.18% | -20.09% | -20.09% | -20.09% |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.42B | -13.23% | 2.90% | 3.78% | 8.12% |
| Disc Medicine, Inc. (IRON)vs › | $2.44B | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-340.2%
Net Profit Margin
-928.4%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-05-31 | -990.10% |
| 2026-02-28 | -1394.34% |
| 2025-11-30 | -576.13% |
| 2025-08-31 | -1094.77% |
| 2025-05-31 | -98.66% |
| 2025-02-28 | -305.38% |
| 2024-11-30 | -440.75% |
| 2024-08-31 | -388.91% |
| 2024-05-31 | -368.39% |
| 2024-02-29 | -250.33% |
| 2023-11-30 | -276.77% |
| 2023-08-31 | -200.26% |
| 2023-05-31 | -79.14% |
| 2023-02-28 | -321.11% |
| 2022-11-30 | -688.74% |
| 2022-08-31 | -423.58% |
| 2022-05-31 | -397.14% |
| 2022-02-28 | -442.09% |
| 2021-11-30 | -509.76% |
| 2021-08-31 | -281.26% |
| 2021-05-31 | -372.05% |
| 2021-02-28 | -484.43% |
| 2020-11-30 | -297.71% |
| 2020-08-31 | -453.29% |
| 2020-05-31 | 181.25% |
| 2020-02-29 | -432.65% |
| 2019-11-30 | -726.05% |
| 2019-08-31 | -22.94% |
| 2019-05-31 | -32.50% |
| 2019-02-28 | -29.08% |
